Serotonylation is a chemical process in which serotonin is permanently glued onto a protein, altering that protein’s behavior without any receptor being involved. Most people know serotonin as a brain chemical tied to mood, but only a small fraction of the body’s serotonin is in the brain. The vast majority circulates in the gut and blood, and serotonylation is one of the major ways that peripheral serotonin exerts its effects. Since the process was first named in 2003 in the context of blood clotting, researchers have found it reaching into gene regulation, insulin release, lung disease, cancer biology, and immune programming.
How the Process Works
Serotonylation is a covalent modification, meaning serotonin forms a permanent chemical bond with its target protein rather than just docking temporarily at a receptor. The enzymes responsible are transglutaminases, particularly transglutaminase 2 (TGM2) and, in blood clotting, coagulation factor XIIIa. These enzymes catalyze the attachment of serotonin to specific glutamine residues on target proteins.1PubMed Central. Serotonylation: Serotonin Signaling and Epigenetics The reaction is called transamidation, and once serotonin is linked to the protein, the modification is stable and long-lasting.
What makes serotonylation distinctive is that it bypasses the receptor-based signaling pathways that account for most of serotonin’s known pharmacology. When serotonin binds a receptor on a cell’s surface, the effect is temporary and reversible. Serotonylation, by contrast, changes the protein itself. A small signaling protein called a GTPase, for instance, can be locked into its “on” state by serotonylation, continuously sending a signal that would normally flicker on and off.2PubMed. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release This is a fundamentally different kind of serotonin signaling, one that operates inside the cell rather than at its surface.
The Discovery in Platelets
Serotonylation was first described in blood platelets, the small cell fragments that help form clots. Platelets take up serotonin from the bloodstream and store it in dense granules. When a platelet is activated at the site of an injury, transglutaminases inside the cell attach serotonin to small GTPases such as RhoA and Rab4. This renders the GTPases constitutively active, which drives the release of alpha-granules, packets of growth factors and clotting proteins that platelets dump out to help seal a wound.2PubMed. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release
This finding was significant because it showed that serotonin had a direct intracellular job during clot formation, separate from its well-known ability to stimulate platelet activation through surface receptors. The platelet work also gave the field its vocabulary: the researchers who published the 2003 study coined the term “serotonylation” to describe this receptor-independent mechanism.
Rewriting Gene Expression Through Histones
Perhaps the most surprising turn in serotonylation research came when scientists discovered that the process reaches all the way into the cell nucleus. Histones, the proteins that DNA wraps around, can be serotonylated. Specifically, TGM2 attaches serotonin to glutamine 5 on histone H3, a modification known as H3Q5ser. This mark tends to appear alongside trimethylation of the neighboring lysine 4 (H3K4me3), a well-studied marker of active genes.3PubMed Central. Histone H3Q5 serotonylation stabilizes H3K4 methylation and potentiates its readout
What H3Q5ser appears to do is stabilize that trimethylation mark and enhance its ability to recruit the protein complexes that read it. In other words, serotonylation on the histone acts as an amplifier, making an already-active gene even more accessible for transcription. This places serotonin in the company of well-established epigenetic regulators like acetylation and methylation. The difference is that serotonin is a neurotransmitter-turned-histone-modifier, a role nobody anticipated when its biochemistry was first mapped decades ago.
Histone serotonylation has been observed in neurons, gut cells, and immune cells, which raises the question of how broadly it operates. The fact that TGM2 is expressed in many tissues suggests the modification could be widespread, though the research is still in relatively early stages when it comes to cataloguing every cell type where it matters.
Regulating Insulin Secretion
The pancreas provided another key example. Beta cells, the insulin-producing cells of the pancreas, contain serotonin and express TGM2. When these cells are stimulated to release insulin, transglutaminases serotonylate two small GTPases, Rab3a and Rab27a, locking them into their active states. These GTPases help drive the machinery that pushes insulin-containing vesicles to the cell surface and releases them. Blocking serotonylation in beta cells reduces insulin secretion.4PubMed Central. Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotonylation
This is a concrete example of serotonin doing something metabolically important without touching a receptor. The beta cell essentially uses serotonylation as a way to keep the insulin-release machinery engaged during periods of high demand. It also hints at why serotonin levels in the gut and pancreas might matter for metabolic health in ways that have nothing to do with mood.
Vascular Remodeling and Pulmonary Hypertension
One of the more clinically urgent areas of serotonylation research involves pulmonary arterial hypertension (PAH), a progressive disease in which the arteries of the lungs thicken and stiffen. Serotonin has long been implicated in PAH, but serotonylation appears to be a key mechanism through which it does damage. When serotonin enters smooth muscle cells lining pulmonary arteries, TGM2 serotonylates several intracellular proteins, driving those cells to proliferate and migrate in ways that narrow the vessels.5PubMed Central. Role of Protein Transamidation in Serotonin-Induced Proliferation and Migration of Pulmonary Artery Smooth Muscle Cells
Among the proteins serotonylated in this context are fibronectin, a structural protein in the tissue surrounding blood vessels, and the signaling molecule RhoA. Elevated TGM2 activity and increased serotonylation of fibronectin and RhoA have been found in lung tissue from animal models of pulmonary hypertension as well as in blood from patients with the disease.6PubMed Central. Transglutaminase 2-mediated serotonylation in pulmonary hypertension The serotonylation of fibronectin correlates with disease progression, making it a potential biomarker as well as a mechanistic player. The overall picture is that serotonylation sits at the intersection of serotonin transport into vascular cells, structural remodeling of the vessel wall, and the growth signaling that sustains both.
Cancer Connections
Serotonylation has surfaced in several cancer contexts, and the evidence so far suggests it can promote tumor growth through more than one route. In pancreatic cancer, histone serotonylation reprograms the metabolism of tumor cells. Knocking down TGM2 in pancreatic cancer cells reduced histone serotonylation and led to a significant decrease in cell proliferation, colony formation, and tumor growth in mice, while simultaneously increasing cancer cell death.7Nature Communications. Histone serotonylation promotes pancreatic cancer development via lipid metabolism remodeling The mechanism appears to involve serotonylation-driven changes in lipid metabolism genes, giving the cancer cells an energy advantage.
A separate line of research has linked serotonylation to immune evasion by tumors. Serotonin can increase the expression of PD-L1, the protein that many cancers display on their surface to hide from immune attack, and this upregulation occurs through serotonylation of small G proteins inside the cancer cell.8PubMed. Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models In mouse models, reducing peripheral serotonin levels improved the effectiveness of immune checkpoint blockade therapy, a class of drugs already in wide clinical use. This raises the possibility that manipulating serotonin levels or blocking serotonylation could make existing immunotherapies work better.
In colon cancer, researchers found that targeting the serotonin transporter (the protein that pumps serotonin into cells) suppressed the serotonylation of mTOR, a master growth regulator. When mTOR was no longer serotonylated, it became inactive, which in turn shifted the cell’s handling of tryptophan, the amino acid precursor to serotonin.9PubMed Central. Targeting SERT promotes tryptophan metabolism: mechanisms and implications in colon cancer treatment These findings illustrate how intertwined serotonin transport, serotonylation, and metabolic reprogramming are in the tumor microenvironment.
Immune Programming
The immune system is emerging as another arena where serotonylation has a surprisingly specific job. In allergic airway inflammation, activated platelets release serotonin that then enters macrophages, the immune cells that coordinate inflammatory responses. Inside the macrophage, TGM2 catalyzes histone H3Q5 serotonylation, which pushes the macrophage toward what is called alternative activation, a state that amplifies the type 2 immune response responsible for allergic inflammation.10Cellular & Molecular Immunology. Platelet-derived serotonin epigenetically programs macrophage alternative activation to orchestrate type 2 airway inflammation
What is remarkable here is the circuit: platelets, which are not conventionally thought of as immune regulators, supply the serotonin that epigenetically reprograms a different cell type. This kind of transcellular serotonylation, where the serotonin originates in one cell and modifies histones in another, expands the concept well beyond what was imagined when the process was first studied in isolated platelets. It also suggests that serotonylation could be a factor in asthma and other allergic diseases, though therapeutic applications remain speculative at this point.
Beyond Serotonin
Serotonin is not the only monoamine neurotransmitter that can be grafted onto proteins by transglutaminases. Dopamine and noradrenaline can be attached to proteins through the same enzymatic mechanism, a process sometimes called monoaminylation.11PubMed. Transglutaminase-mediated transamidation of serotonin, dopamine and noradrenaline to fibronectin: evidence for a general mechanism of monoaminylation Histamine, too, has been shown to undergo a similar conjugation to histone glutamines via TGM2.12Trends in Biochemical Sciences. Serotonylation: A Deep Dive into Its Role in Cellular Regulation
The implication is that the cell has a general-purpose toolkit for attaching small amine-containing molecules to proteins, and serotonylation is simply the best-studied instance. Dopaminylation of histones has already been reported as an epigenetic modification in its own right. If histaminylation proves to have similarly broad effects, the scope of monoamine-based protein modifications could be far larger than current research has mapped. For now, serotonylation remains the most thoroughly investigated example, in part because peripheral serotonin is so abundant and because the platelet work gave the field a head start.
How Researchers Track Serotonylation
Identifying which proteins get serotonylated, and exactly where on those proteins the modification sits, is a non-trivial technical challenge. Serotonin is small and does not behave like the more commonly studied protein modifications, so standard proteomics workflows needed to be adapted. One approach uses a chemically modified serotonin analog that carries a small clickable handle. Cells take up this analog and incorporate it into proteins through the normal serotonylation machinery. Researchers then use click chemistry to attach a tag that lets them pull serotonylated proteins out of a complex mixture. Using this strategy, one group identified 46 proteins with 50 distinct serotonylation sites.13PubMed. Characterization of protein serotonylation via bioorthogonal labeling and enrichment
More recently, a method based on a rapid azo-coupling reaction was developed to profile serotonylation across the proteome of cancer cells. This technique exploits the chemical properties of the serotonin ring structure and was able to identify serotonylation sites on key regulatory proteins including myosin-9, plectin, and ubiquitin protein ligase E3 component N-recognin 4.14PubMed Central. pH-Controlled Chemoselective Rapid Azo-Coupling Reaction (CRACR) Enables Global Profiling of Serotonylation Proteome in Cancer Cells The fact that these are structural and signaling proteins involved in cell shape, movement, and protein turnover suggests serotonylation touches more cellular processes than the handful that have been studied in detail so far.
These proteomic tools matter because they shift the field from a candidate-based approach, where researchers test whether a specific protein is serotonylated, to an unbiased screen that asks what the full landscape looks like. The 46-protein catalog from the earlier study and the expanding lists from newer work represent a map that is still filling in, and each newly identified target potentially opens a fresh line of investigation into what serotonylation is doing in a given tissue or disease.
Pharmacological Angles
From a drug-development perspective, serotonylation sits at an interesting crossroads. TGM2 is the primary enzyme that installs the modification, and several existing compounds inhibit transglutaminases. Cystamine, for example, is a well-characterized transglutaminase inhibitor that has been shown to block protein serotonylation in cell culture.15PubMed. Serotonin–more than a neurotransmitter: transglutaminase-mediated serotonylation of C6 glioma cells and fibronectin The trouble is selectivity: TGM2 does many things in many tissues, including roles in wound healing, extracellular matrix stabilization, and apoptosis. Broadly blocking TGM2 would likely produce side effects that outweigh any benefit from reducing serotonylation in one disease context.
A more targeted strategy might involve reducing the serotonin supply to cells rather than inhibiting the enzyme. Blocking the serotonin transporter (SERT), which is how cells bring serotonin inside, could starve the serotonylation reaction of its substrate. SSRIs, the widely prescribed antidepressants, block SERT in the brain, but their effects on peripheral serotonin dynamics and serotonylation in non-neuronal tissues remain poorly understood. The colon cancer work showing that SERT inhibition suppressed mTOR serotonylation hints at a link worth exploring, though repurposing SSRIs for cancer therapy is speculative and far from clinical testing.9PubMed Central. Targeting SERT promotes tryptophan metabolism: mechanisms and implications in colon cancer treatment
Another angle involves tryptophan hydroxylase 1 (TPH1), the enzyme that produces serotonin outside the brain. Inhibiting TPH1 in mouse tumor models lowered peripheral serotonin, reduced PD-L1 expression on cancer cells through reduced serotonylation, and improved the response to checkpoint immunotherapy.8PubMed. Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models TPH1 inhibitors would leave brain serotonin untouched (brain serotonin is made by a different enzyme, TPH2), sidestepping the mood-related concerns that come with manipulating central serotonin. No TPH1 inhibitor has been approved for cancer use, but the logic is cleaner than trying to block TGM2 itself.
Why Serotonylation Stayed Under the Radar
Given how many cellular processes serotonylation appears to influence, it is fair to wonder why the modification was not discovered sooner and why it remains relatively obscure compared to phosphorylation or acetylation. Part of the answer is technical. The tools to detect serotonylation at specific protein sites only became available in the last decade, and the modification is chemically distinct enough from the standard post-translational marks that it does not show up in routine proteomics screens. Another factor is disciplinary: serotonin research historically lived in neuroscience and pharmacology, where the focus was on receptors and synaptic transmission. The idea that serotonin could permanently modify proteins inside non-neuronal cells simply was not on the radar of most researchers until the platelet work forced a rethink.
The broader monoaminylation framework, recognizing that dopamine, histamine, and potentially other amines undergo the same kind of conjugation, is even newer. TGM2-mediated histone monoaminylation is now recognized as an emerging class of epigenetic mark with roles in gene transcription across multiple tissue types.12Trends in Biochemical Sciences. Serotonylation: A Deep Dive into Its Role in Cellular Regulation As proteomic coverage improves and more labs adopt the newer enrichment techniques, the catalog of serotonylated (and dopaminylated, and histaminylated) proteins will grow, and with it, the list of diseases and processes where these modifications play a role. The field is still closer to its beginning than its middle.